Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

The following is a summary of “Associations between a healthy lifestyle score and retinal neurovascular health,” published in ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema ...

Moderate to severe obstructive sleep apnea was associated with significantly higher odds of having neovascular age-related macular degeneration, according to a study published in Clinical & ...

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to ...